The search for the aetiology of Bartter's syndrome (BS) continues to beckon investigators from diverse disciplines. The aetiology remains as elusive as the disease is uncommon. The search has, nonetheless, brought in its wake an array of physiological abnormalities of considerable clinical interest. Several hypotheses have been put forward, each in turn losing favour, less from disproof as from failure to establish proof before new observations lead to an alternative proposal. Meanwhile the spin-off from these studies continues to add to knowledge of hormonal interactions, volume and blood pressure regulation, and electrolyte homeostasis. Though frequently familial, histocompatibility studies reveal no genetic marker (Watson et al. 1982) . The cardinal clinical feature is hypokalaemia, a consequence of inappropriate kaliuresis. The cause of this kaliuresis is what the search has been about. First defined in 1962 (Bartter et al. 1962) this seems an appropriate time to review its current status and speculate on future directions.
The first description of hyperplasia of the renin-producing juxtaglomerular (JG) apparatus as a histologic entity was in Bartter's index cases (Bartter et al. 1962 ). This characteristic is invariably accompanied by hyperreninaemia and, by consequence, elevated plasma angiotensin II which in turn results in hyperaldosteronism. The conspicuous absence of hypertension in this setting results from a demonstrable resistance of the vasculature to the pressor action of angiotensin II. This vascular resistance initially appeared as a likely cause of the syndrome, since such a defect would predictably result in increased renin synthesis to accelerate angiotensin production and help prevent excessive hypotension. Angiotensin resistance has subsequently been reported in a variety of clinicopathological states bearing little resemblance to BS (Kaplan & Silah 1964) . Nor is the vascular unresponsiveness of BS specific for angiotensin but, as in other conditions, is also seen following noradrenaline infusions (Silverberg et al. 1978) . In addition, neither adrenalectomy (Trygstad et al. 1969 ) nor aminoglutethimide (Goodman et al. 1969 ) correct the hypokalaemia, excluding secondary aldosteronism as its cause. The same criticisms exclude the proposal of primary JG hyperplasia (with secondary angiotensin tachyphylaxis) as the cause of the syndrome. Furthermore, JG hyperplasia has also been reported in a variety of clinicopathological states including potassium depletion (Sealey et al. 1970) . Much knowledge has been gained on the renin-angiotensin-aldosterone axis as a result of these studies but hypokalaemia, the cardinal feature of BS, remains unexplained.
The more recent recognition of hyperplasia of the interstitial renomedullary cells on renal biopsy in BS (Verberckmoes et al. 1976 ) set in motion a number of interesting studies, since these cells are production sites of renal prostaglandins. PgE is elevated in the urine in BS (Gill et al. 1976) , as are PgI (prostacyclin) metabolites (Gullner et al. 1980) . Prostaglandins have considerable potential relevance in BS including an antagonism to the vasoconstrictor effect of angiotensin (Lonigro et al. 1973) , stimulation of renin (Weber et al. 1976 ), kallikrein (Haluska et al. 1977) mepacrine normalized urinary PgE in BS with no effect on the syndrome's other manifestations, including potassium balance (Delaney et al. 1981) . Rather akin to hyperaldosteronism, the increased prostaglandin production may aggravate the syndrome but does not cause it. The same holds true for the subsequent demonstration of abnormalities in the kallikrein-kinin system (Lechi et al. 1976 , Vinci et al. 1978 . The potentially natriuretic, vasodilatory effects of the hyperbradykininaemia seen in BS do not seem to playa primary pathogenetic role, nor does the kallikrein inhibitor aprotinin (Trasylol) affect the manifestations of the syndrome including potassium balance (Delaney et al. 1981) . Underlying all of these studies has been the potential natriuretic effect these hormones might have, thereby increasing sodium delivery to tubular sites of potassium secretion with resultant hypokalaemia. What emerges is a syndrome characterized by a marked imbalance of vasoactive hormones occurring as a consequence rather than as a cause of BS. Failure to account for the syndrome's cardinal feature, hypokalaemia, remains.
Though not explicable on the basis of the natriuretic effects of a particular hormone, there is now incontrovertible evidence of abnormal sodium handling in BS (Delaney et al. 1981 , White 1972 , Gill & Bartter 1978 . Saline loading results in exaggerated natriuresis. Free water clearance is impaired, an observation attributable to impaired sodium chloride reabsorption in the ascending limb of the loop of Henle. In two landmark articles in March 1973 (Rocha & Kokko 1973 , Burg & Green 1973 , based on the lumen-positive potential difference across this nephron segment, it was concluded that chloride is actively transported in the ascending limb with sodium following passively. Based on these observations and a reduced distal fractional chloride reabsorption, Gill & Bartter (1978) proposed a defect in chloride reabsorption in the loop of Henle as a likely cause of the syndrome. Such a defect would impair the passive reabsorption of both sodium and potassium at this site. The fact that ouabain, a specific inhibitor of Na-K-ATPase, reduces the lumen-positive potential difference at this site (Rocha & Kokko 1973 , Burg & Green 1973 is difficult to reconcile with the notion of active chloride transport.
Based on an analysis of previous studies in gallbladder and kidney, an alternative hypothesis has recently been proposed (Westenfelder & Kurtzman 1981) which in essence concludes that sodium is actively transported at this site and that the chloride theory may have been an over-simplification. This led to the proposal of impaired loop sodium reabsorption as the proximal defect in BS, with hypokalaemia as a consequence of increased sodium delivery to tubular sites of potassium secretion as the only viable explanation of the syndrome based on current knowledge (Westenfelder & Kurtzman 1981) . It is also true that such a sodium-losing defect could result in most of the documented manifestations of the syndrome (Bourke & Delaney 1981) . Many experimental observations are not, however, explicable on this basis. Salt loading stimulates rather than suppresses the hyperprostaglandinuria (Delaney et aJ. 1981) . Failure to normalize angiotensin resistance, hyperreninaemia or hyperprostaglandinuria has been reported despite significant positive sodium balance in BS (Delaney et al. 1981) . The failure of prostaglandin synthetase inhibitors to correct the hypokalaemia after several months, despite complete abolition of the exaggerated natriuresis (Delaney et al. 1981) , is difficult to reconcile with a primary salt-losing defect. Furthermore, the data on which the hypothesis is based, namely that impaired free water clearance indicates decreased NaCI reabsorption in the ascending limb, presupposes both adequate suppression of antidiuretic hormone and the absence of inappropriate water reabsorption in thecollecting duct, neither of which has been substantiated in BS. Finally, potassium depletion per se can result in reduced tubular NaCl reabsorption (Garella et al. 1970) , attributable to a defect in the ascending limb of the loop of Henle (Luke et al. 1978) .
Could it be that the cardinal feature of BS is also the proximate cause? In the maze of interdigitating derangements (Figure 1 ) could the obvious have been partially overlooked? Is BS the consequence of a primary potassium-losing tubulopathy? The possibility has recently been suggested (Bargette & Stein 1978 ), but Westenfelder & Kurtzman (1981 dismissed the notion for the following five reasons: (1) Experimental dog studies indicate that potassium depletion causes metabolic acidosis in contrast to the alkalosis of BS. (2) The degree of hyperreninaemia seen in BS exceeds that seen in potassium depletion per se. (3) The hyperaldosteronism could not be explained since hypokalaemia inhibits aldosterone release.
(4) The vasopressin-resistant concentrating defect persists on restoration of normokalaemia. (5) Potassium administration aggravates the hyperprostaglandinuria.
We feel that none of these criticisms disqualifies the potassium theory. While it is true that potassium depletion causes metabolic acidosis in the dog (Hulter et al. 1980 ), this does not appear to be so in the rat (Adler et al. 1974) or man (Huth et al. 1959) . The degree of hyperreninaemia in some cases reported from Bartter's laboratory has been moderate at most (Bartter et al. 1976 ) and substantial hyperreninaemia has been reported in experimental potassium depletion (Galvez et al. 1977) . Moreover, the degree of JG hyperplasia seen in BS is not more prominent than that seen in other clinical hypokalaemic states (Pasternack & Perheentupa 1966) . There is no doubt that hypokalaemia per se inhibits aldosterone release whether it be a primary event or secondary to some other abnormality. Nonetheless, the consequences of excessive renal potassium leakage include a host of pathophysiological derangements (Figure 1 ) which as a secondary phenomenon would tend to have a stimulatory effect on aldosterone secretion. Thus a balance may be struck, and frequently is in BS, resulting in normal aldosterone levels despite marked hypokalaemia on the one hand and marked hyperreninaemia on the other. The reported failure of restoration of normokalaemia to correct the tubular concentrating defect (Zipser et al. 1979 ) was a short-term study. It would be hardly surprising if such a defect, due to prolonged potassium depletion, would reverse slowly if at all. The fact that potassium loading exacerbated rather than corrected the hyperprostaglandinuria (Zipser et al. 1979 ) may seem at first sight to argue against a primary potassium-losing tubulopathy. Potassium loading in BS, however, does not cause potassium repletion. Rather it exaggerates the kaliuresis. It can be likened to the exaggerated natriuresis on sodium loading in BS where augmentation of urinary PgE excretion is also seen (Delaney et al. 1981 ).
On the positive side, whereas former concepts of renal physiology necessitated increased sodium delivery to potassium secretory sites for excess kaliuresis to occur, current concepts are entirely compatible with the possibility of a primary potassium-losing tubulopathy (Sebastian et al. 1982) . A defect of the collecting duct luminal membrane with either impaired reabsorption or leakage of cellular potassium could result in renal potassium wasting, which is not dependent on aldosterone but amplified by hyperaldosteronism. If this transport defect also affected the macula densa region, increased renin secretion might be predicted. Also on the positive side is the fact that many of the consequences of Bartter's syndrome "have been" demonstrated in potassium depletion. These include not only the JG hyperplasia and hyperreninaemia already referred to, but angiotensin resistance (Radfar et al. 1978) , hyperprostaglandinuria (Weber et al. 1978) , low urinary kinins (Vinci et al. 1978) , and impaired tubular NaCl reabsorption (Garella et al. 1970 , Luke et al. 1978 Fleischer et al. 1969) . The secondary and tertiary consequences involve a series of potential amplifying or modulatory loops represented diagrammatically in Figure 1 .
To prove or disprove a primary potassium-losing tubulopathy is, we believe, the present challenge in Bartter's syndrome. One outcome would end the search. Either outcome will add to the syndrome's pre-eminence as a formidable vehicle for increasing understanding of renal function in health and disease.
